Penbrook Management’s Meridian Bioscience Inc VIVO Stock Holding History

Penbrook Management’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-49,175	Closed	-$1.01M	–	110
2015 Q4	$1.01M	Sell	49,175 -575	-1%	-$11K	1.03%	34
2015 Q3	$851K	Sell	49,750 -225	-0.5%	-$4.11K	0.9%	42
2015 Q2	$931K	Buy	49,975 +225	+0.5%	+$4.17K	0.88%	46
2015 Q1	$949K	Buy	+49,750	New	+$920K	0.84%	48

Other funds holding VIVO

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Penbrook Management's VIVO Position: Q1 2016 in Review

Penbrook Management sold out of Meridian Bioscience Inc (VIVO) in Q1 2016, closing a stake of 49,175 shares — an estimated $1.01M sold.

Penbrook Management first reported a position in VIVO in Q1 2015 and held it in 4 quarters. The position peaked at $1.01M in Q4 2015. 172 funds tracked by Wall St. Rank hold VIVO as of Q1 2016.

Penbrook Management reported no remaining Meridian Bioscience Inc position as of Q1 2016 after selling out during the quarter.
Penbrook Management sold 49,175 Meridian Bioscience Inc shares in Q1 2016, an estimated $1.01M.
Penbrook Management first reported a position in Meridian Bioscience Inc in Q1 2015 and held it in 4 quarters.
Penbrook Management's Meridian Bioscience Inc position peaked at $1.01M in Q4 2015.
172 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2016.

Based on Penbrook Management's 13F filing for Q1 2016, filed 21 Apr 2016.